We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Expert Opinion / Interview · April 11, 2020

Overall Survival From Extended Follow-Up of a Trial of Nivolumab and Ipilimumab for the First-Line Treatment of Advanced Renal Cell Carcinoma

Interview by
Sumanta Kumar Pal MD
Interview with
Jun Gong MD


Additional Info

Disclosure statements are available on the authors' profiles:

Further Reading